Martin Shkreli Hearing: See All The Times 'Pharma-Bro' Smirked During Congressional Meeting [PHOTO]
"Pharma-Bro" Martin Shkreli didn't seem to express any remorse during his Congressional hearing on drug prices and his federal fraud charges.
Who Were The Most Hated People Of 2015?
In fact, the former Turing Pharmaceuticals CEO not only plead the fifth on every single question he was asked during his hearing, but also managed to smirk and roll his eyes throughout the entire appearance.
He smirked on more than one occasion--like whenever members of the Congressional committee seemed to speak at all (which earned an eye roll):
Martin Shkreli, the one thing you should never do before Congress is roll your eyes. pic.twitter.com/DVpHkcOUY9
— Scott McGrew (@ScottMcGrew) February 4, 2016
'Pharma Bro' Arrested For Securities Fraud
When he spoke back to Representative Trey Gowdy about whose advice he was actually willing to take:
"I intend to follow the advice of my counsel, not yours," Martin Shkreli tells congressman. https://t.co/0ZSNkeliIl pic.twitter.com/dGixx0vxpi — NBC Bay Area (@nbcbayarea) February 4, 2016
When he was reminded that his actions put people's lives in jeopardy:
"It's not funny, Mr. Shkreli. People are dying and they're getting sicker and sicker" #PeopleNotProfits pic.twitter.com/1sd5mGDhpF
— HumanRightsCampaign (@HRC) February 4, 2016
And when he continued, over and over, to Plead the Fifth:
Wath Martin Shkreli troll Congress by taking the Fifth over and over: https://t.co/EmpIjFhXnD pic.twitter.com/uNTA7WBubP — Slate (@Slate) February 4, 2016
After he was excused from the hearing, Shkreli even took to his own Twitter page to show that he was genuine with how he acted--and again, had no regrets.
Hard to accept that these imbeciles represent the people in our government. — Martin Shkreli (@MartinShkreli) February 4, 2016
I had prior counsel produce a memo on facial expressions during congressional testimony if anyone wants to see it. Interesting precedence. — Martin Shkreli (@MartinShkreli) February 4, 2016